Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 4Lymphoid 3Breast 3Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromatin Immunoprecipitation Sequencing × Genitourinary × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡